Sravan Kumar Emany
Sravan Kumar Emany's purchase track record
Sravan Kumar Emany has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/4/2024 | IRWD | $100K | -27.0% | -46.6% | +7.8% |
| 9/15/2023 | IRWD | $300K | +33.5% | +8.2% | +15.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Kyverna Reports Positive One-Year Data for Miv-cel Trials. Kyverna Therapeutics disclosed one‑year data from its Miv‑cel trials in stiff person syndrome and generalized myasthenia gravis, showing durable responses and a favorable safety profile. The CEO noted that the high disease burden supports a premium pricing strategy. These results reinforce the potential of a single‑dose therapy to reduce long‑term treatment burden.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Ironwood Pharmaceuticals names Tammi Gaskins as CEO. Ironwood Pharmaceuticals announced that Tammi Gaskins will become chief executive officer on Jan. 1, 2027. The leadership change comes as the stock is trading near a long‑standing support level around $4.04. The appointment adds a fresh perspective to Ironwood’s management team and may be relevant to its ongoing operations and pipeline.
Transaction History
| BEAM | ▲ Buy | Grant | 31,750 | $0 | 3/31/2026 | View on chart |
| KYTX | ▲ Buy | Grant | 11,006 | $0 | 2/24/2026 | View on chart |
| BEAM | ▼ Sell | Open Market | 6,294 | $171K | 12/31/2025 | View on chart |
| BEAM | ▲ Buy | Grant | 80,000 | $0 | 12/31/2024 | View on chart |
| IRWD | ▼ Sell | Open Market | 11,001 | $45K | 11/18/2024 | View on chart |
| IRWD | ▼ Sell | Tax Withholding | 18,280 | $121K | 5/16/2024 | View on chart |
| IRWD | ▲ Buy | Option Exercise | 37,120 | $0 | 3/8/2024 | View on chart |
| IRWD | ▲ Buy | Open Market | 10,684 | $100K | 3/4/2024 | View on chart |
| IRWD | ▲ Buy | Grant | 65,312 | $0 | 2/12/2024 | View on chart |
| IRWD | ▼ Sell | Tax Withholding | 41,332 | $616K | 2/8/2024 | View on chart |
| IRWD | ▲ Buy | Grant | 85,000 | $0 | 1/17/2024 | View on chart |
| IRWD | ▼ Sell | Tax Withholding | 6,661 | $63K | 11/16/2023 | View on chart |
| IRWD | ▲ Buy | Open Market | 36,072 | $300K | 9/15/2023 | View on chart |
| IRWD | ▲ Buy | Grant | 74,236 | $0 | 3/8/2023 | View on chart |
| IRWD | ▼ Sell | Open Market | 6,578 | $76K | 11/21/2022 | View on chart |
| IRWD | ▲ Buy | Grant | 85,000 | $0 | 12/6/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Beam Therapeutics to present BEAM-301 data at ESGCT congress
Beam Therapeutics is scheduled to present initial data from its Phase 1/2 trial of BEAM-301 for Glycogen Storage Disease Type Ia at the 33rd Annual Congress of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. This upcoming presentation is a key catalyst for the stock, which is currently trading near the lower end of its 52-week range. The company is also highlighted in a list of high-beta stocks where short sellers are active, suggesting elevated volatility potential around the data release.
Beam Therapeutics to present BEAM-301 data at ESGCT congress. Beam Therapeutics is scheduled to present initial data from its Phase 1/2 trial of BEAM-301 for Glycogen Storage Disease Type Ia at the 33rd Annual Congress of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. This upcoming presentation is a key catalyst for the stock, which is currently trading near the lower end of its 52-week range. The company is also highlighted in a list of high-beta stocks where short sellers are active, suggesting elevated volatility potential around the data release.